New PARP Drug 'Could Benefit Most Ovarian Cancer Patients'

Patients with platinum-sensitive recurrent ovarian cancer showed significantly improved disease-free survival with niraparib (Tesaro), regardless of underlying genetic mutation status, in the first phase 3 trial to be conducted with a poly(ADP)-ribose polymerase (PARP) inhibitor.

The results showed that progression-free survival (PFS) improved by 73% in patients with a BRCA mutation (genetic change sometimes found in patients with hereditary breast/ovarian cancer) and by 55% in those without such mutations.

The new data were presented  at the 2016 European Society for Medical Oncology (ESMO) Congress and simultaneously published in the New England Journal of Medicine.